Study summary

A BTK inhibitor pill raised platelets for months in people who had failed many treatments

LUNA3 trial (rilzabrutinib) · 202 people, phase 3 · Published June 2025, Blood; FDA approved August 2025

23%durable platelet response, vs 0% with placebo

What was tested

Rilzabrutinib, a twice-daily BTK inhibitor pill that calms the immune attack on platelets, against placebo, in adults with persistent or chronic ITP.

What they found

What it means

The first BTK inhibitor approved for ITP, adding an oral option with a new mechanism.

Blood, via PubMed ↗ ← Back to the outlook
Last reviewed 2026-11-16 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.